Profile data is unavailable for this security.
About the company
Dr. Reddy’s Laboratories Limited is an India-based global pharmaceutical company. The Company offers a portfolio of products and services, including active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC). Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. The Company’s segments include Pharmaceutical Services and Active Ingredients, Global Generics, and Others. The Pharmaceutical Services and Active Ingredients segment primarily consists of the Company’s business of manufacturing and marketing APIs and intermediates. The Global Generics segment consists of the Company’s business of manufacturing and marketing prescription and OTC finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).
- Revenue in USD (TTM)3.25bn
- Net income in USD626.15m
- Incorporated1984
- Employees25.86k
- LocationDr Reddy's Laboratories Ltd8-2-337, Road No.3 Banjara HillsHYDERABAD 500034IndiaIND
- Phone+91 4 049002900
- Fax+91 4 049002999
- Websitehttps://www.drreddys.com/
More ▼
Mergers & acquisitions
| Acquired company | DRREDDY:NSI since announced | Transaction value |
|---|---|---|
| Menolabs LLC | 8.80% | 3.00m |
Data delayed at least 15 minutes, as of May 06 2024 08:53 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Catalent Inc | 4.10bn | -1.30bn | 10.23bn | 17.80k | -- | 2.77 | -- | 2.50 | -7.18 | -7.18 | 22.52 | 20.37 | 0.3878 | 4.09 | 3.00 | 230,224.70 | -12.32 | 2.88 | -14.02 | 3.26 | 17.94 | 31.03 | -31.77 | 6.35 | 1.71 | -0.625 | 0.5758 | 0.00 | -11.22 | 11.59 | -153.00 | -- | 26.69 | -- |
| Exact Sciences Corp | 2.50bn | -204.15m | 11.41bn | 6.50k | -- | 3.58 | 4,640.74 | 4.57 | -1.14 | -1.14 | 13.81 | 17.34 | 0.3937 | 5.32 | 13.82 | 384,579.40 | -3.22 | -9.71 | -3.47 | -10.60 | 73.83 | 74.10 | -8.17 | -28.21 | 2.07 | -- | 0.4311 | -- | 19.93 | 40.63 | 67.26 | -- | -3.71 | -- |
| United Therapeutics Corporation | 2.50bn | 1.05bn | 11.63bn | 1.17k | 12.42 | 2.17 | 10.52 | 4.66 | 21.13 | 21.13 | 50.24 | 120.76 | 0.3891 | 2.50 | 11.31 | 2,138,956.00 | 16.36 | 10.38 | 18.03 | 11.27 | 88.87 | 91.47 | 42.05 | 29.25 | 3.64 | -- | 0.101 | 0.00 | 20.20 | 7.41 | 35.40 | 10.89 | 4.55 | -- |
| Natera Inc | 1.08bn | -434.80m | 11.85bn | 3.28k | -- | 15.15 | -- | 10.95 | -3.80 | -3.80 | 9.41 | 6.40 | 0.7634 | 15.49 | 4.14 | 329,851.00 | -30.66 | -36.17 | -39.20 | -46.60 | 45.52 | 45.88 | -40.16 | -56.15 | 3.96 | -- | 0.3219 | -- | 31.99 | 33.26 | 20.63 | -- | 58.81 | -- |
| Charles River Lbrtrs ntrntl Inc | 4.13bn | 474.62m | 12.03bn | 20.00k | 25.30 | 3.33 | 15.14 | 2.91 | 9.23 | 9.23 | 80.25 | 70.06 | 0.5228 | 8.19 | 5.39 | 206,470.50 | 6.08 | 6.46 | 7.09 | 7.62 | 36.89 | 36.99 | 11.63 | 11.58 | 1.16 | 4.97 | 0.4203 | 0.00 | 3.86 | 12.75 | -2.39 | 16.69 | 17.86 | -- |
| Incyte Corp | 3.77bn | 745.44m | 12.07bn | 2.52k | 16.32 | 2.24 | 14.53 | 3.20 | 3.29 | 3.29 | 16.64 | 24.02 | 0.5827 | 4.52 | 5.50 | 1,492,815.00 | 11.53 | 9.07 | 14.16 | 11.02 | 93.73 | 94.97 | 19.78 | 13.68 | 3.43 | -- | 0.006 | 0.00 | 8.87 | 14.45 | 75.42 | 40.41 | -15.06 | -- |
| BIO-TECHNE Corp | -100.00bn | -100.00bn | 12.15bn | 3.05k | -- | 6.03 | -- | -- | -- | -- | -- | 12.81 | -- | -- | -- | -- | -- | 9.57 | -- | 10.20 | -- | 67.35 | -- | 21.91 | 2.88 | -- | 0.1619 | 24.19 | 2.81 | 12.07 | 4.88 | 25.13 | 12.81 | 0.00 |
| Medpace Holdings Inc | 1.96bn | 312.32m | 12.16bn | 5.80k | 40.00 | 18.07 | 35.79 | 6.20 | 9.81 | 9.81 | 61.73 | 21.72 | 1.23 | -- | 7.31 | 332,680.00 | 19.58 | 13.94 | 46.20 | 23.18 | 27.99 | 28.84 | 15.92 | 15.23 | -- | -- | 0.00 | -- | 29.17 | 21.76 | 15.26 | 31.17 | 17.99 | -- |
| Sarepta Therapeutics Inc | 1.40bn | 16.90m | 12.63bn | 1.31k | 1,677.67 | 13.14 | 215.07 | 9.00 | 0.0797 | 0.0797 | 14.75 | 10.17 | 0.4466 | 0.5758 | 4.66 | 1,067,960.00 | 0.5378 | -21.63 | 0.6577 | -25.75 | 88.18 | 86.65 | 1.20 | -77.05 | 3.44 | -- | 0.5632 | -- | 33.26 | 32.80 | 23.81 | -- | 6.30 | -- |
| Dr Reddy's Laboratories Ltd (ADR) | 3.25bn | 626.15m | 12.67bn | 25.86k | 20.01 | 3.90 | 15.88 | 3.89 | 3.76 | 3.76 | 19.53 | 19.29 | 0.7954 | 2.01 | 3.54 | 125,815.20 | 15.31 | 9.63 | 20.71 | 13.77 | 58.28 | 54.55 | 19.24 | 12.69 | 1.87 | -- | 0.069 | 18.75 | 14.69 | 11.60 | 91.22 | 32.32 | 4.04 | 8.75 |
| Viatris Inc | 15.43bn | 54.70m | 14.03bn | 38.00k | 278.29 | 0.6911 | 5.02 | 0.9092 | 0.0423 | 0.0423 | 12.81 | 17.05 | 0.3158 | 2.49 | 5.09 | 405,971.10 | 0.112 | 0.0887 | 0.1315 | 0.1061 | 43.64 | 40.29 | 0.3546 | 0.2891 | 1.22 | 2.79 | 0.4696 | 560.11 | -5.14 | 6.17 | -97.37 | -30.53 | -16.88 | -- |
| Neurocrine Biosciences, Inc. | 1.98bn | 369.70m | 14.15bn | 1.45k | 38.67 | 5.93 | 36.09 | 7.14 | 3.64 | 3.64 | 19.47 | 23.72 | 0.6797 | 1.10 | 4.71 | 1,415,714.00 | 12.68 | 9.77 | 15.58 | 12.19 | 98.05 | 98.51 | 18.65 | 14.79 | 2.47 | -- | 0.049 | -- | 26.76 | 33.13 | 61.62 | 63.90 | 2.67 | -- |
| Biomarin Pharmaceutical Inc | 2.47bn | 205.46m | 15.65bn | 3.40k | 78.03 | 3.08 | 50.37 | 6.33 | 1.06 | 1.06 | 12.77 | 26.74 | 0.3715 | 0.4993 | 4.00 | 726,740.40 | 3.09 | 0.7773 | 3.54 | 0.8825 | 79.22 | 76.30 | 8.31 | 2.24 | 1.70 | -- | 0.1766 | 0.00 | 15.42 | 10.16 | 18.43 | -- | -5.74 | -- |
Data as of May 04 2024. Currency figures normalised to Dr Reddy's Laboratories Ltd's reporting currency: US Dollar USD
8.01%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RBC Global Asset Management (UK) Ltd.as of 31 Dec 2023 | 2.21m | 1.33% |
| Robeco Institutional Asset Management BVas of 31 Mar 2024 | 1.97m | 1.18% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 1.86m | 1.12% |
| Goldman Sachs Asset Management LPas of 31 Dec 2023 | 1.58m | 0.95% |
| Aperio Group LLCas of 31 Dec 2023 | 1.31m | 0.79% |
| Aikya Investment Management Ltd.as of 31 Dec 2023 | 1.10m | 0.66% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 994.61k | 0.60% |
| Dimensional Fund Advisors LPas of 31 Dec 2023 | 829.31k | 0.50% |
| Numeric Investors LLCas of 31 Dec 2023 | 765.19k | 0.46% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 742.92k | 0.45% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
